Last reviewed · How we verify

NCT06151717

A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma

Completed Last updated 17 June 2025
What this trial tests

trial testing Non-Interventional Study in Multiple Myeloma in 50 participants. Completed in 5 June 2025.

Timeline
21 September 2023
Primary endpoint
5 June 2025
5 June 2025

Quick facts

Lead sponsorMayo Clinic
StatusCompleted
Study typeOBSERVATIONAL
Enrollment50
Start date21 September 2023
Primary completion5 June 2025
Estimated completion5 June 2025
Sites4 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

Eligibility, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the outcomes of patients undergoing initial therapy for multiple myeloma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Non-Interventional Study

Trials testing the same drug.

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06151717.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing